Revenio Group Corporation: Managers' Transactions – Robin Pulkkinen
Revenio Group Corporation | Stock Exchange Release | February 16, 2024 at 17:30:00 EET
Person subject to the notification requirement
Name: Robin Pulkkinen
Position: Chief Financial Officer
Issuer: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04
Notification type: INITIAL NOTIFICATION
Reference number: 52730/7/6
Transaction date: 2024-02-15
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009010912
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 500 Unit price: 26 EUR
(2): Volume: 500 Unit price: 27.5 EUR
(3): Volume: 500 Unit price: 26.5 EUR
(4): Volume: 100 Unit price: 28 EUR
(5): Volume: 500 Unit price: 27 EUR
Aggregated transactions (5):
Volume: 2100 Volume weighted average price: 26.80952 EUR
For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
[email protected]
Distribution
Nasdaq Helsinki
FIN-FSA
Key media
www.reveniogroup.fi
Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.
In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.